The design, modeling, synthesis and biological activity evaluation of two hybrid agents formed by 7-oxyiminomethylcamptothecin derivatives and diaminedichloro-platinum (II) complex are reported. The compounds showed growth inhibitory activity against a panel of human tumor cell lines, including sublines resistant to topotecan and platinum compounds. The derivatives were active in all the tested cell lines, and compound 1b, the most active one, was able to overcome cisplatin resistance in the osteosarcoma U2OS/Pt cell line. Platinum-containing camptothecins produced Platinum-DNA adducts and topoisomerase I-mediated DNA damage with cleavage pattern and persistence similar to SN38, the active principle of irinotecan. Compound 1b exhibited an appreciable antitumor activity in vivo against human H460 tumor xenograft, comparable to that of irinotecan at lower well-tolerated dose levels and superior to cisplatin. The results support the interpretation that the diaminedichloro-platinum (II) complex conjugated via an oxyiminomethyl linker at the 7-position of the camptothecin resulted in a new class of effective antitumor compounds.
Introduction
The antitumor activity of cis-diaminedichloro-platinum (II) (cisplatin or cDDP, Chart 1) was first reported by Rosenberg et al. in 1969 [1] . The success of cisplatin paved the way for the second and third-generation platinum(II) drugs, carboplatin and oxaliplatin (Chart 1). Presently, platinum-based coordination complexes are among the most widely used antitumor agents in the clinic [2] .The effectiveness of cisplatin lies in its ability to covalently bind DNA, leading to important changes in the helical structure. In spite of the efficacy of platinum-based treatment regimens, long-term cure is difficult to obtain. The major drawbacks include a) severe and sometimes life-threatening toxic side effects; b) activation of drug resistance mechanisms by tumor cells; c) inadequate intratumor concentration of the drug and tumor microenvironmental interactions; d) relatively poor pharmacokinetic profiles and e) increased DNA repair capacity [3, 4, 5] .
Chart 1
Recently, major effort has been made to develop new platinum complexes. Often, the strategies were aimed to increase cellular uptake and/or facilitate targeting of the compounds to DNA [6] .The latter approach involves the incorporation of a functional group into the platinum complex that interacts or intercalates with DNA. Numerous conjugates have been prepared in which the Pt moiety has been tethered to high-affinity nucleic acid ligands, such as doxorubicin [7] , acridine [8] , amines or peptides [9] , anthraquinones [10] and short oligonucleotides [11] . In particular, a mixed platinum(II) complex with doxorubicin demonstrated antitumor activity against a variety of tumor cell lines, including doxorubicin-and cisplatin-resistant cell lines. Moreover, in contrast to the highly toxic doxorubicin/cisplatin combination, the doxorubicin-platinum complex was not associated to an increase in toxicity [7] .
As part of our program aimed to advance DNA as a drug target, we were interested in devising novel platinum containing dual compounds that interacted in an effective way with DNA and in addition accomplished the requirements of solubility in the body fluids and improved cellular uptake. In this context, a promising approach seemed to be the conjugation of platinum to analogues of the natural antitumor compound camptothecin (CPT).
CPTs [12] are widely used for the treatment of human cancers [13] . They exhibit a unique mechanism of action because they target the topoisomerase I (Topo I), forming a ternary complex For this reason, (E)-7-oxyminomethyl CPTs were selected for conjugation to Pt(II) [19] . Initially, we focused on the most promising 7-substituted compound in our hands, 3a (Figure 1 ). As the molecule is characterized by a terminal amino group, we planned to link the CPT moiety to Pt(II) through an amide bond. Thus, the synthesis of compound 1a (Figure 1 ), designed as our first conjugate, was devised to proceed by coupling of 3a with 2,3-diaminopropionic acid followed by complexation of the derived diamine (2a) with a suitable platinum salt .
Figure 1
Prior to start the synthesis, we studied the binding mode of compound 1a to the Topo I covalent complex with DNA [24] . A two-step protocol was used to obtain a better estimate of the orientation of the ligands within the binding site. First, the non-platinated ligands were correctly placed within the binding site using the molecular docking technique. On the basis of the geometry of interaction thus obtained, the platinated ligands were built and analyzed using the QM/MM approach. To gain insight into the role of the linker on the interaction with the target, we also modelled the binding of a series of derivatives 1 with different carbon chain length (n= [1] [2] [3] [4] . Molecular modelling showed that the compound with six carbons (n = 3, 1b) demonstrated the best interactions. Thus, for the sake of clarity, here we describe only the target-drug interactions of compound 1b compared to 1a.
The intercalation binding site for all of the studied compounds was located between the +1 (upstream) and -1 (downstream) base pairs of the uncleaved strand, which effectively ''open'' the DNA duplex. Comparative analysis of the best poses obtained for the four non-platinum-containing compounds (2a-b, 3a-b) revealed their common behavior of intercalating at the site of DNA cleavage, forming base-stacking interactions with both the -1 and +1 base pairs. There is evidence of two direct hydrogen bonds between the Asp 533 and Arg 364 residues of the enzyme and the planar skeleton of the investigated derivatives, in perfect agreement with the CPT-DNA complex structure [24] . The greatest differences were found by analyzing the behavior of the side chains. For 2a, the side chain was too short and allows only a partial interaction with the DNA duplex, leading one of the two amino groups to interact with O 6 and N 7 of G 11 , whereas the immine nitrogen interacts weakly with N 6 A 113 . For both 2b and 3b, the greater length of their side chains allows them to interact more efficiently with the DNA duplex. The amino group of 3b forms three strong hydrogen with N 7 G 11 , whereas 2b forms a hydrogen bond to N 6 A 113 , two between the amino group and O 6 G 12 and the last with N 7 G 11 . The interactions between derivatives 2a and 2b and the DNA-Topo I complex are given in Figure 2 (together with the experimental DNA-Topo I structure (PBD code 1T8I), where the interactions listed as dotted green lines represent the intermolecular hydrogen bonds.
Figure 2
Orientations of the systems described above (2a and 2b) were used to assemble the two Pt complexes (1a and 1b), which were further analyzed using the QM/MM mixed approach on the platinated complexes. This QM/MM mixed approach allowed us to obtain a better and more complete description of the interactions of the two Pt complexes with the DNA-Topo I system, as well as an evaluation of the structural changes induced in the complex by the binding of ligands 1a and 1b. Major differences were observed at the level of the side chain, whereas the CPT ring maintained its position inside the DNA-Topo I system ( Figure 3 ).
Figure 3
The compound with the longer spacer (1b) is more effective in its interaction with the DNA duplex than the one with the shorter side chain (1a). Both complexes are stabilized by the formation of two hydrogen bonds between O 6 G 12 and an amino group bound to the platinum atom that lies in the square planar coordination plane with a small distortion of the Pt-N 7 bond due to the destacking of the bases. Compound 1b is further stabilized by two interactions with N 7 G 11 and N 6 A 113 , the same as those previously discussed for 2b. Indeed, the complex formation induces a distortion of the DNA duplex, with a partial destacking of the nucleotide bases, which is less marked in the case of compound 1b. The shift of G 12 in the complex with 1a is significantly larger (7.1 Å) than in the complex with 1b (5.4 Å), in poor agreement with the guanine position in the crystal structure.
Moreover, the hydrophobic face of the guanine base for 1a is even more solvent exposed than for 1b, giving rise to an additional source of instability of the 1a complex. It should be noted that in Figures 2 and 3 , the best poses for derivatives 1 and 2 with only S absolute configuration at the stereogenic center on the diamine moiety are reported. The best poses for the corresponding R diastereomers did not show striking differences with regard to chirality, indicating that the stereochemistry of the diamine moiety does not seem to play a role in the interaction with DNA.
On the basis of molecular modeling results, the synthesis of compounds 1a and 1b was carried out.
Compound 1a was prepared from the corresponding 7-oxyminomethylCPT 3a [19] , which in turn was obtained from 7-formylCPT (4). The oxime was then condensed with N,N-bis-tbutoxycarbonyl-2,3-diaminopropanoic acid in the presence of WSC and HOBt as condensing agents. The Boc-diamine 5a was quantitatively deprotected with TFA in CH2Cl2 to obtain the bistrifluoroacetate 6a. Reaction with K2PtCl4 [25] afforded 1a in 69% yield (Scheme 1).
Scheme 1
The synthesis of compound 1b required the preparation of the longer-chain hydroxylamine 8 (Scheme 2). Protection of 6-aminohexanol with (Boc)2O, followed by Mitsunobu reaction with Nhydroxyphthalimide, afforded compound 7. Hydrazinolysis and subsequent deprotection from the Boc group with 5.9 M HCl at 0°C afforded hydroxylamine 8 hydrochloride. Condensation with 7-formylCPT (4) by refluxing in ethanol in the presence of pyridine afforded oxime 3b.
Following the same synthetic approach described for compound 1a, the bistrifluoroacetate 6b was obtained in 65% overall yield from 3b. Disappointingly, in this case the reaction with K2PtCl4 gave compound 1b in low yield and unsatisfactory purity, due to a troublesome separation of the desired compound from the salt 6b. Thus, a different strategy was followed. The cisdichlorobis(diaminopropionic acid hydrochloride) platinum (II) complex was first prepared in high yield by reacting 2,3-diaminopropionic acid hydrochloride with K2PtCl4 in H2O [26] and then condensed with 3b to give 1b in 89% yield (Scheme 2). Scheme 2 2.2 Antiproliferative activity studies. The antiproliferative effect of the derivatives 1a-b and 6a-b was determined at 1 h exposure on different human tumor cell lines, including cell lines resistant to TPT and platinum compounds ( Table 1 ). TPT and cDDP were used as reference drugs. All the tested compounds were generally more potent than cDDP on all the selected cell lines, including those resistant to cDDP, oxaliplatin and TPT. In contrast, a comparison between the new CPT-Pt derivatives and TPT revealed cell line-dependent drug potency. A superior cytotoxicity with respect to TPT was evidenced for 1b and 6b on the H460 cell line, since 6a and 1a are less potent than TPT. All the compounds were less potent that TPT in the squamous cell carcinoma A431 cell line, including the corresponding sublines resistant to TPT (A431/TPT) and cDDP (A431/Pt). The compounds were less potent than TPT in the osteosarcoma U2OS cell line and, with the exception of 1b, such behavior was observed also in the corresponding cDDP-resistant variant (U2OS/Pt). A general reduced potency with respect to TPT was observed in ovarian carcinoma IGROV-1 and A2780 cell lines. This was also evident in the corresponding cDDP and oxaliplatin-resistant sublines with the exception of 1b in IGROV-1/Pt and 1b and 6b in IGROV-1/OHP cells.
Table 1
As regards the resistance index (ratio between IC50 values of resistant and sensitive cells), the contribution of the Pt(II) complex was demonstrated by the reduced resistance indexes observed for CPT-Pt derivatives with respect to cDDP and TPT in several human tumor cell lines. The resistance index of CPT-Pt (1a and 1b) was higher than that of cDDP and TPT in A431/TPT cells.
Conversely, a reduced resistant index with respect to TPT and cDDP was observed for the two hybrid compounds in A431/Pt, U2OS/Pt, IGROV-1/Pt, IGROV-1/OHP and A2780/CP cells.
It is noteworthy that the most active derivative 1b was effective in overcoming cDDP resistance in osteosarcoma cDDP-resistant U2OS cells ( Table 1 and Figure 4 ).
Figure 4
To clarify the role of the Pt(II) complex in drug activity, the ratio between the IC50 of compounds not containing Pt and the IC50 of compounds containing Pt (6a/1a or 6b/1b) was considered. A ratio higher than 1 indicates the positive effect produced by the Pt atom. As reported in Figure 4 , the role of the Pt atom appears more important for the potency of 1b than for 1a. Indeed, considering the 11 cell lines evaluated, the ratios were < 1 in six cell lines for 6a/1a and only in two cell lines for 6b/1b.
Drug combination studies. Drug combination experiments using platinum compounds with
CPTs are widely documented [27] . Synergism was evidenced in various human tumor cell lines [27] . Indeed, the presence of Pt-DNA adducts in the substrate DNA inhibited Topo I activity,
whereas it enhanced CPT action on the cleavable complex [28] . The effect of the combination of cDDP and our derivatives (6a-b) on antiproliferative activity was evaluated on the H460 cell line ( Figure 5 ). To this purpose, cells were simultaneously exposed for 1h to increasing concentrations of CPTs and to subtoxic concentration (10 µM) of cDDP ( Figure 5 ).The data demonstrated that, as for the combination of cDDP with TPT, the combination of 6a-b with cDDP resulted in a synergistic interaction, thus supporting the rational of joining the two moieties into a single molecule.
Figure 5
2.4 Topoisomerase I-dependent DNA cleavage assay. TopoI-mediated DNA cleavage experiments were performed to investigate the ability of the new compounds to stimulate DNA damage. SN38 was used as reference compound. As reported in Figure 6 , a dose-dependent precipitation of labeled DNA in the wells was observed for CPT-Pt derivatives (1a and 1b). This behavior was drug-and enzyme-dependent since it was not observed in the presence of cDDP, 6b, or in the absence of TopoI.
Figure 6
Stabilization of the ternary cleavable complex was evaluated by adding a high salt concentration 2.5 Drug uptake and DNA platination. Drug uptake and DNA platination were evaluated in H460 cells exposed for 1 h to equitoxic (IC50 cDDP = 22 µM; 1a = 4.1 µM; 1b = 0.4 µM) or equimolar (0.4 µM) concentrations of compounds. cDDP was used as reference drug. As reported in Figure   8A , at equitoxic concentrations a marked cellular uptake of 1a was observed. It is noteworthy that the uptake of 1b was comparable to that of cDDP, in spite of its 55-fold lower concentration. As regards the exposure to equimolar drug concentration (0.4 µM), a significantly higher cellular Pt accumulation was evidenced for 1a (P< 0.02) and 1b (P< 0.01) with respect to cDDP ( Figure 8B ).
DNA platination was studied in H460 cells exposed for 1 h to equitoxic (IC50) concentrations of compounds. Pt-DNA adducts were revealed in the DNA extracted from cells treated with both 1a and 1b ( Figure 8C ). DNA-bound Pt was significantly higher in cells exposed to cDDP than 1a and 1b (P< 0.02). The finding is expected, because the low potency of cDDP required the use of substantially higher concentrations (IC50 cDDP = 22 µM). In contrast, the exposure of H460 cells to equimolar concentration of drugs (0.4 µM) resulted in DNA platination only in cells treated with 1b (data not shown). (Figure 9 ). CPT and cDDP were used as references.
cDDP exhibited similar growth inhibitory potency on both pEMBLyex4 and pEZ-2hTop1 transformed yeasts, indicating that cDDP potency was unaffected by the presence/absence of TopoI.
Conversely, cell growth of yeast cells expressing human TopoI was affected by the exposure to
No important change in cell growth was observed for yeast cells transformed with the empty vector and treated with CPTs. Interestingly, a significant increase (P< 0.01) in DNA platination was documented in yeasts expressing human TopoI and treated with CPT-Pt with respect to yeasts transformed with empty vector ( Figure 9B ). Altho ugh less relevant, a significant change (P< 0.02) in the amount of Pt-DNA adducts was also observed for transformed yeasts treated with cDDP.
Figure 9
2.7 Effect of DNA Topoisomerase I on the formation of Pt-DNA adducts. CPT derivatives (1ab, 6a-b) were tested for their capability to bind the DNA by evaluating the migration of pCMV6neo plasmid in agarose gel electrophoresis after drug exposure ( Figure 10 ). In comparison to cDDP and SN38, which did not produce any effect on DNA migration, the exposure of plasmid DNA to 1a revealed a significantly reduced migration of the vector. Such behavior was likely dependent on the major capability of 1a to produce Pt-DNA adducts. The effect was less marked for 1b. Moreover, the simultaneous exposure of pCMV6neo plasmid to TopoI and 1a or 1b produced DNA accumulation in the wells, thus resembling that observed in cleavage assays. Such behavior was dependent on the presence of TopoI, since it was not observed in the absence of enzyme or in the presence of human serum albumin (BSA). Interestingly, degradation of the protein by SDS and proteinase K before loading on agarose gel produced a different behavior depending on the compound. No change in DNA migration was evidenced with respect to un-proteolized sample for plasmid exposed to 1b, whereas a migration similar to the control was obtained when DNA treated with 1a and TopoI was exposed to SDS/proteinase K before loading.
To evaluate the effect of TopoI on platination of the plasmid DNA, pCMV6neo was exposed to 1b or cDDP in the presence and absence of TopoI in a cell-free system. As reported in Figure 10B , the Pt-DNA adducts were significantly increased by the addition of purified human TopoI in the presence of both cDDP (P< 0.05) and 1b (P< 0.02).
Figure 10
2.8 In vivo antitumor activity. On the basis of the promising results observed in vitro, compound 1b was selected for further preclinical development. Mice bearing non-small cell lung cancer H460 carcinoma tumor xenograft were treated with 1b administered intravenously (i.v.) according to the intermittent q4dx4 schedule (Table 2. ). Compound 1b exhibited antitumor activity comparable to that of irinotecan and higher than that of cDDP, both delivered at their maximum tolerated doses.
Considering the toxicity profile, 1b was well tolerated (no lethal toxicity and no body weight loss) with respect to cDDP (1/5 toxic deaths).
Table 2

Conclusions
Platinum drug administration is associated with dose-limiting side effects, off-target effects and relatively poor pharmacokinetic profiles. In particular, the low cellular uptake and the rapid metabolic inactivation of platinum compounds imply that the amount of active drug reaching the target is low. As regards CPTs, the reversibility of the DNA cleavage may represent a limitation of drug efficacy, resulting in resistance of slowly growing tumors. In an attempt to overcome such drawbacks, hybrid 7-oxyiminomethyl CPTs containing a Pt(II) complex were synthesised.
Molecular modeling studies evidenced that the CPT moiety of the hybrid drugs overlapped TPT in the cleavable complex, independently of the absolute configuration of the stereogenic center on the diamine moiety. The most efficient interaction with duplex DNA was observed for compound 1b, thus supporting a critical role of the linker to provide drug-DNA interaction. CPT-Pt derivatives were effective antiproliferative agents, with potency similar/superior to TPT and in general more potent than cDDP. The potential advantage of the Pt(II) complex was also supported by the reduced resistance indexes observed for CPT-Pt derivatives with respect to cDDP and TPT in several human tumor cell lines. It is noteworthy that the most active derivative 1b was effective in overcoming cDDP resistance in osteosarcoma cDDP-resistant U2OS cells. More importantly, CPT-Pt exhibited activity both as a Topo I poison and as a DNA-platinating molecule, thus indicating that the conjunction of the two components in a one hybrid molecule did not negatively impact on their properties as single drugs. Interestingly, results obtained in a cell-free system and in experiments involving yeast cells documented two relevant findings produced by the presence of Topo I: i) DNA platination produced by the CPT-Pt molecules was increased in the presence of Topo I, and ii) the presence of Topo I, but not BSA, produced a dose-dependent accumulation of DNA in the wells of agarose and acrylamide gels, thus evoking a network organization involving DNA, CPT-Pt and Topo I. It could be speculated that the network effect observed at a high concentration might be the result of CPT-Pt acting outside, rather than inside, the active site of Topo I. Thus, a scenario in which the Pt atoms form covalent bounds linking the DNA and the Topo I outside the active site should be considered as a possible alternative/additional mechanism of drug action. This aspect remains to be properly investigated.
Concerning antitumor activity, preliminary in vivo data indicated that compound 1b was well tolerated and exhibited promising antitumor potency, comparable to that of irinotecan and superior to that of cDDP. The widely used combinations of CPTs with platinum compounds exhibit synergism in terms of both efficacy and toxicity. Thus, the good profile of tolerability of the CPT-Pt complex supports additional therapeutic advantages over the drug combinations.
In conclusion, results of the study provide evidence that CPT and a Pt(II) complex joined in a single molecule via an oxyiminomethyl linker could be considered a new class of effective antitumor compounds.
Experimental section
4.1 Chemistry. General Methods. All reagents and solvents were reagent grade or were purified by standard methods before use. Melting points were determined in open capillaries. NMR spectra were recorded with a Bruker AMX 300 spectrometer using TMS as an internal standard. Chemical shifts are given in ppm (δ). Mass spectra were recorded with a Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer APEX II & Xmass software (Bruker Daltonics)-4.7T
Magnet (Magnex). The Elemental Analyses were recorded with a CARLO ERBA EA 1108 instrument. Solvents were routinely distilled prior to use; anhydrous tetrahydrofuran (THF) and ether (Et2O) were obtained by distillation from sodium-benzophenone ketyl; dry dichloromethane was obtained by distillation from phosphorus pentoxide. All reactions requiring anhydrous conditions were performed under a positive nitrogen flow, and all glassware were oven dried and/or flame dried. Isolation and purification of the compounds were performed by flash column chromatography on silica gel 60 (230-400 mesh). Analytical thin-layer chromatography (TLC) was conducted on TLC plates (silica gel 60 F254, aluminum foil). 1, 149.3, 148.6, 145.7, 144.1, 130.8, 130.5, 128.4, 125.8, 125.1, 122.7, 118.8, 97.9,73.9, 73.5, 72.7, 66.2, 55.8, 42.5, 38.9, 31.5, 28.2, 24.8, 7.7 166.9, 166.0, 159.3, 158.8, 157.1, 152.8, 150.5, 149.0, 146.1, 145.5, 131.2, 130.9, 130.3, 128.8, 127.2, 125.3, 124.4, 119.7, 97.4, 97.0, 73.4, 72.8, 65.6, 65.2, 52.5, 50.6, 40.1, 30.7, 8 3-d,l-diamino-N-[2'-(camptothecin-7- 1, 152.9, 150.5, 149.1, 146.3, 145.6, 131.0, 130.3, 128.8, 127.4, 125.4, 124.7, 119.7, 97.2, 73.5, 72.8, 65.6, 61.7, 52.6, 40.7, 39.0, 30.6, 8.2 . HRMS(ESI + ): [M+Na] + calcd for C26H28Cl2N6NaO6Pt 808.0987; found:
{2-tert-
808.0958. Anal. calcd for C26H28 Cl2N6O6Pt: C, 39.70; H, 3.59; Cl, 9.02; N, 10.69, Pt 24.80. Found: C, 39.82; H, 3.44; Cl, 9.35; N, 10.33; hexyl]carbamic acid tert-butyl ester (7). To a solution of (6-hydroxyhexyl)carbamic acid tert-butyl ester [29] 
Molecular modeling.
The five studied camptothecin derivatives were assembled and refined using a systematic conformer search followed by geometry optimization of the lowest energy structure with MOPAC (PM3 Method, RMS gradient 0.0100) [30] . The macromolecule (PDB deposition code: 1T8I) was prepared by removing the camptothecin molecule and adding polar hydrogen atoms, while the side chains of the disordered amino acid residues of the macromolecule complex were checked and rebuilt in DeepView [31] . The individual compounds were prepositioned based on the coordinates of camptothecin from the X-ray structure.
The small molecule compounds and the macromolecule were further processed using the Autodock Tool Kit (ADT) [32] . Gasteiger-Marsili charges [33] were loaded on the small molecules in ADT The dimensions of the grids were thus 80×80×50, with a spacing of 0.200Å between the grid points and the center close to the cavity left by the ligand after its removal. The simpler intermolecular energy function based on the Weiner force field16 in Autodock was used to score the docking results.
Hybrid QM/MM calculations.
In the current study, we used the pseudo-bond ab-initio QM/MM approach as implemented in Gaussian-03 [35] . For the QM/MM calculations, the DNA-Topoisomerase I-ligand system resulting from the docking study was first partitioned into a QM subsystem and an MM subsystem. The reaction system used a smaller QM subsystem consisting of the ligand and bases within 3.5Å, whereas the rest of the system (the MM subsystem) was treated using the AMBER force field, together with a low memory convergence algorithm. The boundary problem between the QM and MM subsystems was treated using the pseudo-bond approach. With this QM/MM system, an iterative optimization procedure was applied to the QM/MM system, using BLYP/PW QM/MM calculations, leading to an optimized structure for the reactants. BLYP-STB and BP-STB calculations were carried out in order to check the dependence of the relative energies on the basis set and exchange correlation functional. The core electrons were frozen up to 4f for Pt, 2p for Cl and 1s for N. For Pt, scalar relativistic effects were taken into account. The convergence criterion used was set to obtain an energy gradient of <10 −4 , using the twin-range cutoff method for non-bonded interactions, with a long-range cutoff of 14Å and a short-range cutoff of 8Å. 4.4 Saccharomyces cerevisiae yeast strain and yeast spot test. JN2-134top1-1 S. cerevisiae strain (MATα rad52::LEU2, trp1, ade2 -1, his7, ura3-52, ise1, top1, leu2) , which lacks the endogenous TOP1 gene, was transformed with the empty vector (pEMBLyex4) or with the same vector containing the wild-type human DNA topoisomerase IB (pEZ-2hTop1) [36] . Yeast cells were maintained at 30°C in synthetic complete medium lacking uracil (uracil-) and supplemented with 2% glucose. For the yeast spot test, cells were growth at 30°C in uracil medium to an OD595 of 0.3.
The yeast culture was then treated with camptothecins or cisplatin for 24 h. After treatment, aliquots of 10 µl were spotted onto plate uracil-. Following 3 days of incubation at 30°C, images were acquired using the IMAGE MASTER VDS (Amersham Pharmacia Biotech). 
Topoisomerase
4.6
Drug accumulation studies. Exponentially growing H460 cells (1x10 6 ) were seeded in 5 cm diameter dishes in triplicate and, 24 h later, they were exposed to equitoxic (IC50) or equimolar (0.4 µM) concentrations of the drugs for 1 h. After treatment, cell monolayers were washed with icecold PBS, scraped, harvested and dissolved in 1 N NaOH. Total cellular Pt content was determined by flameless atomic absorption spectroscopy [37] (Model 3300, Perkin Elmer) or by inductively coupled plasma-mass spectrometry [38] . Cellular Pt levels were expressed as ng/10 6 cells, with cell number determined by counting parallel cultures. For each type of treatment at least three independent experiments were performed. 4.7 DNA platination studies. Exponentially growing H460 cells (3x10 6 ) were seeded in 5 cm diameter dishes in triplicate and, 24 h later, they were exposed to the drugs for 1 h at equitoxic (IC50) or equimolar (0.4 µM) concentrations. DNA was then extracted according to standard procedures involving lysis in the presence of 1 mg/mL proteinase K overnight at 37°C. DNA was then isolated following phenol extraction, ethanol precipitation, RNase treatment, and reprecipitation and finally was dissolved in 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. DNA content was determined spectrophotometrically and platinum content was measured by flameless atomic absorption spectroscopy (Model 3300, Perkin Elmer) or by inductively coupled plasma-mass spectrometry.
For the experiments with yeast cells, JN2-134top1-1 S. cerevisiae strain transformed with pEMBLyex4 or with pEZ-2hTop1 vectors was treated over night with 50 µM drug. Genomic DNA was obtained using MasterPure Yeast DNA purification kit (Epicentre biotechnologies, Wisconsin, USA) and the platinum content measured by inductively coupled plasma-mass spectrometry.
For cell free experiments, pCMV6neo vector (10 µg sample) was treated for 1 h at 37°C with different compounds (50 µM) in the presence and absence of Topo I. After treatment, DNA was isolated following phenol extraction and ethanol precipitation. DNA concentration was determined spectrophotometrically, and platinum content was measured by flameless atomic absorption spectroscopy (Model 3300, Perkin Elmer).
DNA binding of camptothecins.
EcoRV linearized pCMV6neo plasmid was used. Vector (200 ng sample) and CPT analogues (50 µM sample) were incubated in 20 μl of 10 mM Tris-HCl (pH 7.6), 150 mM KCl, 5 mM MgCl2, 0.1 mM dithiothreitol for 1 h at 37°C in the presence/absence of TopoI or BSA. After treatment, samples were loaded on 1% agarose gels or treated with 0.5% SDS and 0.3 mg/ml of proteinase K for 45 min at 42°C (where indicated) and then loaded on 1% agarose gel. The DNA plasmid migration was determined after the ethidium bromide staining.
4.9 Antitumor activity. All experiments were carried out using female athymic Swiss nude mice, 7-10 weeksold (Charles River, Calco, Italy). Mice were maintained in laminar flow rooms keeping temperature and humidity constant. Mice had free access to food and water. Experiments were approved by the Ethics Committee for Animal Experimentation of the Istituto Nazionale Tumori of Milan according to institutional guidelines.
The compound was dissolved in DMSO/cremophor ELP. The solution was maintained at 4°C.
Before the treatment, the drug solution was suspended in cold saline (5+2.5+92.5 of final volume) under magnetic stirring. Drug was delivered in a volume of 10 ml/kg of body weight.
Cisplatinum Teva (clinical) was ready to use. Irinotecan was dissolved in sterile, distilled water keeping it under magnetic stirring for about 2 h.
Exponentially growing tumor cells (10 7 cells/mouse) were s.c. injected into the right flank of athymic nude mice. The tumor line was achieved by serial s.c. passages of fragments (about 2x2x6 mm) from growing tumors into healthy mice as previously described [39] . Tumor fragments were implanted on day 0, and tumor growth was followed by biweekly measurements of tumor diameters with a Vernier caliper. Tumor volume (TV) was calculated according to the formula: TV (mm 3 ) = d2xD/2 where d and D are the shortest and the longest diameter, respectively. Drugs were delivered i.v. every fourth day for four times (q4dx4) starting when tumors were just palpable. The efficacy of the drug treatment was assessed as tumor volume inhibition percentage (TVI%) in treated versus control mice, calculated as: TVI% = 100-(mean TV treated/mean TV control x 100). The toxicity of the drug treatment was determined as body weight loss and lethal toxicity. Deaths occurring in treated mice before the death of the first control mouse were ascribed to toxic effects. a Cell sensitivity to drug was assessed by growth-inhibition assay. Twenty-four h after seeding, cells were exposed to drug for 1 h and then, after an additional 72 h, counted using a cell counter. The reported value is the IC50 expressed in µM (drug concentration inhibiting growth by 50%). In parenthesis is reported the resistance index (ratio between IC50 values of resistant and sensitive cells). Data represent mean values ± S.D. from at least 3 independent experiments. 
